Rosiek, V.; Bocian-Jastrzębska, A.; Kos-Kudła, B.
Selected Serum Biomarkers (Leptin, Chromogranin A, CA19-9, CEA) in Patients with Pancreatic Neuroendocrine Neoplasm and Associations with Metabolic Syndrome. Cancers 2023, 15, 2348.
https://doi.org/10.3390/cancers15082348
AMA Style
Rosiek V, Bocian-Jastrzębska A, Kos-Kudła B.
Selected Serum Biomarkers (Leptin, Chromogranin A, CA19-9, CEA) in Patients with Pancreatic Neuroendocrine Neoplasm and Associations with Metabolic Syndrome. Cancers. 2023; 15(8):2348.
https://doi.org/10.3390/cancers15082348
Chicago/Turabian Style
Rosiek, Violetta, Agnes Bocian-Jastrzębska, and Beata Kos-Kudła.
2023. "Selected Serum Biomarkers (Leptin, Chromogranin A, CA19-9, CEA) in Patients with Pancreatic Neuroendocrine Neoplasm and Associations with Metabolic Syndrome" Cancers 15, no. 8: 2348.
https://doi.org/10.3390/cancers15082348
APA Style
Rosiek, V., Bocian-Jastrzębska, A., & Kos-Kudła, B.
(2023). Selected Serum Biomarkers (Leptin, Chromogranin A, CA19-9, CEA) in Patients with Pancreatic Neuroendocrine Neoplasm and Associations with Metabolic Syndrome. Cancers, 15(8), 2348.
https://doi.org/10.3390/cancers15082348